S773 Rapidity of Symptom Control with Upadacitinib Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Results From Two Randomized Phase 3 Studies
Pourquoi ce travail est dans la base
Une base qui oublie comment elle a trouvé un travail ne peut pas être vérifiée. Voici les voies qui ont admis celui-ci.
Notice bibliographique
Résumé
Introduction: Upadacitinib (UPA) is an oral, selective JAK inhibitor investigated for treatment of several immune-mediated inflammatory diseases, including ulcerative colitis (UC). Safety and efficacy of UPA in patients (pts) with moderately to severely active UC were studied in the phase 3 induction trials, U-ACHIEVE (NCT02819635) and U-ACCOMPLISH (NCT03653026). We assessed early (week 2) symptomatic improvement and decrease in biomarkers of inflammation during induction therapy with UPA 45 mg once daily (QC) compared with placebo (PBO). Methods: In the multicentre, double-blind, PBO-controlled U-ACHIEVE and U-ACCOMPLISH trials, pts with moderately to severely active UC were randomized 2:1 to UPA 45 mg QD or PBO for 8 weeks. This analysis evaluated the proportions of pts with clinical remission (per partial Mayo score), clinical response (per partial Mayo score), stool frequency subscore (SFS) ≤1, and rectal bleeding subscore (RBS) of 0, as well as change from baseline in fecal calprotectin and high-sensitivity C-reactive protein (hsCRP) at week 2 with UPA vs PBO. Statistical comparison between the two groups was performed according to the Cochran-Mantel-Haenszel test adjusted for baseline corticosteroid use (yes or no), baseline Adapted Mayo score (≤7 or >7), according to prior biologic response (bio-IR, biologic inadequate response/bio failure; non-bio-IR, nonbiologic inadequate response/non-bio-failure). Results: As early as week 2, a significantly higher proportion of pts who received UPA achieved clinical remission per partial Mayo score (23%) compared with PBO (5%; treatment difference, [95% CI]: 17.4 [11.8, 23.1]; P < 0.001) in U-ACHIEVE. Results were similar in U-ACCOMPLISH at week 2: UPA (31%) versus PBO (3%); treatment difference (95% CI): 26.5 (20.9, 32.1; P < 0.001). Similarly, higher proportions of pts receiving UPA 45 mg QD achieved other efficacy endpoints, including clinical response, SFS ≤1 and RBS = 0, at week 2 vs PBO (Table 1). Significant decreases from baseline in markers of inflammation (fecal calprotectin and hsCRP levels) were also observed with UPA vs PBO in both trials (Table 1). Safety was comparable with the known safety profile of UPA, and no new safety signals were identified. Conclusion: UPA 45 mg QD achieved rapid improvement in both symptomatic and objective biomarker measures as early as week 2 compared with PBO in pts with moderately to severely active UC. The results demonstrate rapid onset of treatment effect with UPA.Table 1.: Baseline Clinical Characteristics of Patients with Perianal Crohn's Disease
Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.
Prédiction distillée sur la base complète
Imitation des enseignantsNi prévalence calibrée, ni vérité terrain. Validation humaine à venir. Apprise à partir de 10 348 étiquettes directes de Codex et de 10 348 étiquettes directes de Gemma. Le mode candidate est l'union des têtes enseignantes seuillées; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont ni des étiquettes humaines ni des étiquettes directes de modèles de pointe.
Scores Codex et Gemma par catégorie
| Catégorie | Codex | Gemma |
|---|---|---|
| Métarecherche | 0,001 | 0,000 |
| Méta-épidémiologie (sens strict) | 0,000 | 0,000 |
| Méta-épidémiologie (sens large) | 0,002 | 0,000 |
| Bibliométrie | 0,000 | 0,000 |
| Études des sciences et des technologies | 0,000 | 0,001 |
| Communication savante | 0,000 | 0,000 |
| Science ouverte | 0,000 | 0,000 |
| Intégrité de la recherche | 0,000 | 0,000 |
| Charge utile insuffisante (le modèle a refusé de juger) | 0,000 | 0,000 |
Scores machine (provisoires)
Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.
Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.
score_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découle